TIZIANA LIFE SCIENCES LTD (TLSA) Stock Price, Quote, News and Overview
NASDAQ:TLSA - Nasdaq - BMG889121031 - Common Stock - Currency: USD
TLSA Quote, Performance and Key Statistics
0.9
-0.02 (-2.45%)
The current stock price of TLSA is 0.9 USD. In the past month the price increased by 12.94%. In the past year, price increased by 79.93%.
TLSA Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 19.85 | 354.98B | ||
| AMGN | AMGEN INC | 15.03 | 159.99B | ||
| GILD | GILEAD SCIENCES INC | 23.87 | 137.10B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 1656.31 | 123.40B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.25 | 76.09B | ||
| ARGX | ARGENX SE - ADR | N/A | 39.34B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 32.37B | ||
| BNTX | BIONTECH SE-ADR | N/A | 28.26B | ||
| ONC | BEIGENE LTD-ADR | N/A | 26.06B | ||
| NTRA | NATERA INC | N/A | 22.20B | ||
| BIIB | BIOGEN INC | 8.32 | 19.98B | ||
| SMMT | SUMMIT THERAPEUTICS INC | N/A | 17.01B |
Related stock screener links
About TLSA
Company Profile
Tiziana Life Sciences Ltd. is a clinical-stage biotechnology company, which engages in the research and development of biotechnological and pharmaceutical products. The firm develops transformative therapies for neurodegenerative and lung diseases. Its clinical pipeline includes drug assets for secondary progressive multiple sclerosis, Crohn's Disease and KRAS+ NSCLC. Its pipeline candidates include Foralumab (TZLS-401), Anti IL-6R mAb (TZLS-501) and Milciclib (TZLS-201). Foralumab (TZLS-401) is a fully human anti-CD3 monoclonal antibody (mAb) for the treatment of Crohn’s and neurodegenerative diseases. Its Anti IL-6R mAb (TZLS-501), a fully human mAb binds to both membrane-bound and soluble forms of IL-6R, an inflammatory cytokine driving chronic inflammation associated with autoimmune disease and cancer, reducing circulating levels of the IL-6 cytokine. Milciclib is a potent, small molecule inhibitor of multiple cyclin-dependent kinases (CDKs), tropomycinreceptor kinases and Src family kinases controlling cell growth and malignant progression of cancer.
Company Info
TIZIANA LIFE SCIENCES LTD
3rd Floor, 11-12 St. James's Square
London SW1Y 4LB GB
CEO: Kunwar Shailubhai
Employees: 9
Company Website: https://www.tizianalifesciences.com/
Investor Relations: https://ir.tizianalifesciences.com/
Phone: 442074952379
TIZIANA LIFE SCIENCES LTD / TLSA FAQ
What is the stock price of TIZIANA LIFE SCIENCES LTD today?
The current stock price of TLSA is 0.9 USD. The price decreased by -2.45% in the last trading session.
What is the ticker symbol for TIZIANA LIFE SCIENCES LTD stock?
The exchange symbol of TIZIANA LIFE SCIENCES LTD is TLSA and it is listed on the Nasdaq exchange.
On which exchange is TLSA stock listed?
TLSA stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for TIZIANA LIFE SCIENCES LTD stock?
7 analysts have analysed TLSA and the average price target is 3.06 USD. This implies a price increase of 240% is expected in the next year compared to the current price of 0.9. Check the TIZIANA LIFE SCIENCES LTD stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is TIZIANA LIFE SCIENCES LTD worth?
TIZIANA LIFE SCIENCES LTD (TLSA) has a market capitalization of 99.59M USD. This makes TLSA a Micro Cap stock.
How many employees does TIZIANA LIFE SCIENCES LTD have?
TIZIANA LIFE SCIENCES LTD (TLSA) currently has 9 employees.
What are the support and resistance levels for TIZIANA LIFE SCIENCES LTD (TLSA) stock?
TIZIANA LIFE SCIENCES LTD (TLSA) has a support level at 0.65 and a resistance level at 0.93. Check the full technical report for a detailed analysis of TLSA support and resistance levels.
Should I buy TIZIANA LIFE SCIENCES LTD (TLSA) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of TLSA, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of TLSA, evaluating the profitability, health, valuation and growth aspects
- TIZIANA LIFE SCIENCES LTD (TLSA) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- TIZIANA LIFE SCIENCES LTD (TLSA) Sales and EPS estimates to see what analysts future expectations are.
- TIZIANA LIFE SCIENCES LTD (TLSA) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- TIZIANA LIFE SCIENCES LTD (TLSA) Insider and Institutional Ownership to learn about the owners and their transactions.
- TIZIANA LIFE SCIENCES LTD (TLSA) Stock Chart to make your own analysis
- TIZIANA LIFE SCIENCES LTD (TLSA) Latest news and press-releases to stay up to date.
Does TIZIANA LIFE SCIENCES LTD (TLSA) stock pay dividends?
TLSA does not pay a dividend.
What is the Price/Earnings (PE) ratio of TIZIANA LIFE SCIENCES LTD (TLSA)?
TIZIANA LIFE SCIENCES LTD (TLSA) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.13).
What is the Short Interest ratio of TIZIANA LIFE SCIENCES LTD (TLSA) stock?
The outstanding short interest for TIZIANA LIFE SCIENCES LTD (TLSA) is 1.71% of its float. Check the ownership tab for more information on the TLSA short interest.
TLSA Technical Analysis
ChartMill assigns a technical rating of 6 / 10 to TLSA. When comparing the yearly performance of all stocks, TLSA is one of the better performing stocks in the market, outperforming 91.3% of all stocks.
TLSA Fundamental Analysis
ChartMill assigns a fundamental rating of 1 / 10 to TLSA. TLSA has a bad profitability rating. Also its financial health evaluation is rather negative.
TLSA Financial Highlights
Over the last trailing twelve months TLSA reported a non-GAAP Earnings per Share(EPS) of -0.13. The EPS increased by 27.54% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -125.21% | ||
| ROE | -740.05% | ||
| Debt/Equity | 0.02 |
TLSA Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 83% to TLSA. The Buy consensus is the average rating of analysts ratings from 7 analysts.